Sarepta Therapeutics, Inc.
SRPT
$20.49
$0.020.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.52% | 68.38% | 80.15% | 65.94% | 40.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.52% | 68.38% | 80.15% | 65.94% | 40.79% |
| Cost of Revenue | 16.92% | 59.19% | 263.02% | 38.62% | 36.68% |
| Gross Profit | -80.34% | 83.24% | -202.24% | 107.63% | 50.26% |
| SG&A Expenses | -28.32% | -0.65% | 5.22% | 24.43% | 6.04% |
| Depreciation & Amortization | 12.46% | 10.98% | 0.00% | -21.23% | 37.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.88% | 36.27% | 176.11% | 33.47% | 26.18% |
| Operating Income | -383.29% | 16,587.45% | -960.58% | 556.57% | 206.50% |
| Income Before Tax | -670.63% | 1,031.60% | -1,025.30% | 325.41% | 202.51% |
| Income Tax Expenses | -3,670.13% | -707.76% | 1,100.79% | 340.23% | -94.91% |
| Earnings from Continuing Operations | -635.38% | 2,947.86% | -1,338.98% | 248.37% | 182.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -635.38% | 2,947.86% | -1,338.98% | 248.37% | 182.10% |
| EBIT | -383.29% | 16,587.45% | -960.58% | 556.57% | 206.50% |
| EBITDA | -238.83% | 1,476.67% | -765.33% | 378.20% | 422.80% |
| EPS Basic | -609.42% | 2,841.43% | -1,296.02% | 238.71% | 176.53% |
| Normalized Basic EPS | -347.15% | 4,068.18% | -853.34% | 451.14% | 237.66% |
| EPS Diluted | -631.44% | 2,662.81% | -1,347.63% | 245.20% | 173.55% |
| Normalized Diluted EPS | -360.22% | 3,913.69% | -894.42% | 407.56% | 230.74% |
| Average Basic Shares Outstanding | 5.08% | 3.58% | 3.59% | 2.85% | 7.31% |
| Average Diluted Shares Outstanding | -0.21% | 7.54% | -1.77% | 11.67% | 13.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |